A recent study demonstrated that deficiency of NEIL3 contributes to chemoresistance through modulating DNA damage repair in prostate cancer [36], suggesting the potential clinical and therapeutic application of NEIL3. This evidence concerns the gene NEIL3 and prostate cancer.